Vancomycin for primary sclerosing cholangitis
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to sign consent before any study procedures
- Be age 15–70, and if you can become pregnant, use effective birth control and have negative pregnancy tests
- Have confirmed large-duct PSC on a bile-duct scan (MRCP/ERCP/PTC)
- Have high liver blood marker ALP (at least 1.5× the upper normal limit)
- Not have bile duct blockage or bile-duct cancer within 6–12 months of starting
- Have stable treatment: no recent antibiotic/probiotic use (3 months), and follow washout rules for other PSC drugs; if you have bowel disease (IBD), it must be mild or in remission
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
This early-phase study tests whether the antibiotic vancomycin can help children with primary sclerosing cholangitis or biliary atresia, and related gut/bile duct problems. It may work by changing gut bacteria, but you would need to avoid certain medicines beforehand.
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
This trial tests whether a fecal (stool) transplant from a healthy donor can help people with both PSC and inflammatory bowel disease. It aims to see if the treatment can improve liver health and reduce inflammation. You must have early to moderate liver scarring and be on stable medications.
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.